HMOX1 and acute myeloid leukemia: The SnMP‐mediated HO1‐inhibition in myeloid cells induces an anti‐tumor immune response via CD8+ T cell adaptive immune responses,[17] and the therapeutic effects of HO1‐inhibiting T‐hNP should be evaluated in an AML patient‐derived xenograft model bearing a human immune system.[38] As described before,[17] HO1 is an enzyme breaking down dying cell released heme, consequently producing biliverdin, Fe2+ and carbon monoxide (CO).